World-first stem-cell therapy shows promise for treating spina bifida in the womb
#stem-cell therapy #spina bifida #fetal surgery #placenta-derived stem cells #myelomeningocele #hindbrain herniation #regenerative medicine #clinical trial
📌 Key Takeaways
- World-first stem-cell therapy applied to fetal spinal cords shows promise for treating spina bifida
- Six pregnant women participated in the trial with no reported complications
- All newborns showed reversal of hindbrain herniation, a serious complication of spina bifida
- Current treatment leaves nearly 60% of children unable to walk independently
- Larger trials needed to confirm effectiveness beyond this small study
📖 Full Retelling
Researchers led by fetal and neonatal surgeon Diana Farmer at the University of California, Davis conducted a groundbreaking clinical trial in February 2026, applying placenta-derived stem cells to the exposed spinal cords of fetuses in utero to treat spina bifida, a severe birth complication affecting movement and continence. The trial involved six pregnant women who underwent surgery at 24-25 weeks of gestation, during which stem cells generated from donated placentas were directly applied to the fetuses' exposed spinal cords. The researchers reported no complications during the surgeries, and the newborns were delivered at around 34 weeks with no signs of infection, cerebrospinal fluid leakage, or tumor growth. All newborns showed reversal of hindbrain herniation, a complication where the back of the brain descends into the neck and blocks cerebrospinal fluid circulation. Currently, standard treatment for myelomeningocele, the most severe form of spina bifida, involves surgery during pregnancy to close the spinal cord defect, but Farmer noted that nearly 60% of children remain unable to walk independently as the procedure doesn't reverse neural damage from amniotic fluid exposure. The stem-cell therapy represents a potential advancement as it aims to repair this neural damage, with previous research showing promising results in sheep models where animals receiving both surgical repair and stem cells regained mobility. While experts like Clare Whitehead from Melbourne's Royal Women's Hospital find the results exciting, they emphasize that positive outcomes in small studies don't always translate to larger populations, and more extensive trials will be needed to confirm the therapy's true effectiveness.
🏷️ Themes
Medical Innovation, Fetal Therapy, Regenerative Medicine
Entity Intersection Graph
No entity connections available yet for this article.
Deep Analysis
Why It Matters
This study represents a significant advancement in the treatment of spina bifida, a debilitating birth defect. The use of stem cells applied directly to the fetal spinal cord shows promise in reversing existing damage and potentially improving neurological outcomes for infants with this condition. It offers a potential alternative to current surgical interventions with limited success.
Context & Background
- Spina bifida affects a significant number of newborns globally, particularly in low-income countries.
- Current surgical interventions for spina bifida often do not fully address the underlying neuronal damage.
- Stem cell research has been explored as a potential therapy for neurological disorders for over a decade.
What Happens Next
Researchers will likely continue to monitor the six newborns in the trial to assess the long-term safety and efficacy of the stem cell therapy. Larger clinical trials involving a greater number of participants are planned to confirm these initial findings and optimize the treatment protocol.
Original Source
NEWS 26 February 2026 World-first stem-cell therapy shows promise for treating spina bifida in the womb Six pregnant women participated in a small trial in which placenta-derived stem cells were applied to fetal spinal cords and the treatment was found to be safe. By Rachel Fieldhouse 0 Rachel Fieldhouse Rachel Fieldhouse is a reporter for Nature in Sydney, Australia. View author publications Search author on: PubMed Google Scholar Email Bluesky Facebook LinkedIn Reddit Whatsapp X Stem cells applied to the exposed spinal cords of fetuses in utero could treat infants with a severe birth complication that affects movement and continence. Researchers report that the therapy is safe, following a small clinical trial in six people 1 . Spina bifida, a condition in which the spinal cord is not properly enclosed during gestation, affects fewer than 1 in 1,000 births globally, but occurs at higher rates in low-income countries. The most severe form, called myelomeningocele, can cause excess fluid accumulation in the brain and potential brain damage, as well as paralysis and issues with bladder and bowel control. Fetal and neonatal surgeon Diana Farmer at the University of California, Davis, led the Cellular Therapy for In Utero Repair of Myelomeningocele trial to assess whether a treatment using stem cells derived from the placenta is feasible and whether it causes harm to pregnant people or their newborns. Six pregnant women underwent surgery at 24–25 weeks of gestation. During the procedure, stem cells generated from donated placentas were applied to the fetuses’ exposed spinal cords directly. The authors say there were no complications during the surgeries, and the newborns were delivered at around 34 weeks of gestation with no signs of infection, cerebrospinal fluid leakage or tumour growth. Farmer says there were concerns that the stem cells could become cancerous. All of the newborns showed signs that a complication of their condition called hindbrain herniation — in w...
Read full article at source